Application of Artificial Intelligence in Early Detection of Eye Complications in Diabetics
Launched by THE NEW MODEL OF CARE, HAIL HEALTH CLUSTER · Dec 14, 2022
Trial Information
Current as of January 17, 2025
Unknown status
Keywords
ClinConnect Summary
In the era of artificial inelegance(AI), a shift from tertiary to secondary and primary care when caring for a patient with diabetic retinopathy is highly recommended.
Due to low operation, AI could be used in the early detection and screening of diabetic retinopathy by application of the service across a mass population and resource-limited areas with a scarcity of eye care services.
AI-based eye care in terms of screening for diabetic retinopathy will make the screening process more effective and cheap and could be delegated to technicians, practitioners, and/or even home-based self-scr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diabetic patients aged 18-90
- Exclusion Criteria:
- • Severely ill patient or patient with cancer
Trial Officials
Khalil Alshammari, VIP Chief MO
Study Chair
Hail Health Cluster
Fakhralddin Elfakki, Researcher at MOC
Principal Investigator
New Model of Care, Hail Health Cluser
Meshari Aljamani, MOC Lead
Study Director
New Model of Care, Hail Health Cluster
About The New Model Of Care, Hail Health Cluster
Hail Health Cluster is a pioneering clinical trial sponsor dedicated to advancing innovative models of care within the healthcare sector. By leveraging collaborative partnerships among healthcare providers, researchers, and community stakeholders, Hail Health Cluster aims to enhance patient outcomes and streamline healthcare delivery through evidence-based practices. Our commitment to rigorous clinical research ensures that we develop and implement effective interventions tailored to meet the evolving needs of diverse populations. With a focus on improving accessibility and quality of care, Hail Health Cluster is at the forefront of transforming healthcare into a more efficient, patient-centered system.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials